Atossa Therapeutics and the Upcoming Conference
Atossa Therapeutics, Inc. (NASDAQ: ATOS) is set to make significant strides in cancer treatment discussions at an upcoming global investment forum. CEO Dr. Steven Quay will engage in a fireside chat panel, bringing his expertise and insights to the forefront regarding the company's innovative approaches in breast cancer therapy.
Dr. Quay's Insights on Breast Cancer Treatments
At the conference, Dr. Quay will delve into the details of Atossa's lead program, focusing on (Z)-endoxifen. This advanced Selective Estrogen Receptor Modulator (SERM) offers unique dual mechanisms of action that may revolutionize the prevention and treatment landscape for women facing breast cancer. The discussion will cover the latest developments, clinical trial results, and the support received from regulatory advisors.
What is (Z)-endoxifen?
(Z)-endoxifen represents a breakthrough in the realm of breast cancer therapeutics. It exhibits a promising profile, potentially providing effective solutions for patients in both prevention and treatment scenarios. Dr. Quay is expected to share compelling data from various ongoing studies that further illustrate the treatment's safety and efficacy.
Engagement at the H.C. Wainwright Conference
The H.C. Wainwright 27th Annual Global Investment Conference, attended by leading investors and analysts, will host this pivotal discussion featuring Dr. Quay. His insights aim to enhance the understanding of breast cancer treatments and the future of Atossa. This platform offers an opportunity for investors to gauge the company's trajectory and upcoming milestones.
Live Presentation and Webcast Availability
For those unable to attend physically, the live presentation will be accessible via webcast. Following the event, a replay will be available for approximately 90 days. Investors and interested parties can watch the session to gain a deeper understanding of Atossa's vision and clinical advancements, especially surrounding (Z)-endoxifen.
Future Connections and Opportunities
Investors intrigued by Atossa's potential are encouraged to connect with the management team during the conference. They can schedule meetings through the HCW conference portal or contact company representatives directly. This engagement allows for a more personal discussion on future developments and investor interests.
About Atossa Therapeutics
Atossa Therapeutics, Inc. is deeply committed to innovating breast cancer prevention and treatment. Focusing on patient-centered science, the company seeks to bring transformative therapies to market. (Z)-endoxifen serves as a cornerstone in their strategy, illustrating their commitment to addressing significant health needs in oncology.
Frequently Asked Questions
What will Dr. Quay discuss at the conference?
Dr. Quay will provide updates on Atossa's clinical programs, particularly focusing on (Z)-endoxifen and its development progress.
How can investors engage with Atossa Therapeutics during the conference?
Investors can schedule meetings with Atossa management via the HCW conference portal or contact company representatives directly.
Where can I access the live presentation?
The live presentation will be webcast and available for replay on Atossa's investor website for 90 days after the event.
What is the significance of (Z)-endoxifen?
(Z)-endoxifen is a new therapy that offers hope for women in breast cancer prevention and treatment, and is being developed to address significant needs in these areas.
What opportunities does Atossa Therapeutics offer to investors?
Atossa provides compelling opportunities for investors interested in innovative biopharmaceuticals targeting breast cancer, particularly through (Z)-endoxifen.
